business / news / / CNBC
Regeneron's (REGN) Dupixent, the approval of the oncology drug linvoseltamab, the anticipated approval of another on.
Regeneron's Dupixent reached $17.8 billion in 2025 sales and is now approved for eight indications.
KEY POINTS
- Regeneron's obesity drug aims to promote weight loss while sparing muscle, unlike current GLP-1s.
- Eylea's U.S. market share is nearly 60%, but Roche's Vabysmo may surpass it by 2027.
- Regeneron's FY2026 revenue is estimated at $15.7 billion, a 9.5% year-over-year increase despite Eylea headwinds.
- The June $700/$850 bull call spread offers a defined-risk way to participate in REGN's potential upside.
COMPANIES
Summarized by Newsio from CNBC. How we summarize →